NORTHERN RNA INC.
$7,000,000.00 CAD
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2022-2023
- Agreement period
- July 28, 2022 – March 22, 2024
- Reference
- nrc-cnrc:172-2022-2023-Q4-1003190
Published purpose
The COVID-19 pandemic has impacted the global supply of nucleic acid products including mRNA and plasmid DNA and delivery vehicles such as lipid nanoparticles which have been demonstrated to be important tools for outbreak management predominately via a mass vaccination approach. The time to market for these products is hindered by complexities in production, production processes, analytical methods, and complicated supply chain, intellectual property landscape and quality management systems. Northern RNA's intention is to provide agile platform production approaches and enabling systems, infrastructure, and resources to ensure access to nucleic acid products and their formulations for researchers, organizations, and healthcare providers in managing the current pandemic and to heighten domestic and global preparedness for the future.
In plain English AI-generated
Northern RNA Inc. receives funding to develop agile production platforms for nucleic acid products like mRNA and lipid nanoparticles, aiming to improve pandemic response and domestic preparedness.
Category: Health Primarily funds activity in Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.